Patient recounts IL‑2 therapy chills, rigors, ICU seizure scare, and recovery—what treatment feels like and why monitoring ...
On March 20, the FDA approved Opdivo for adult and pediatric patients (aged 12 years and older) with previously untreated ...
Learn about superficial spreading melanoma, from the ABCDE diagnostic rules to the latest in immunotherapy, targeted care and surgical options. Superficial spreading ...
Akari’s lead program, AKTX-101, a TROP2-targeting ADC powered by its proprietary PH1 payload, is currently in IND-enabling ...
Day One Biopharmaceuticals, Inc., now part of Servier Group, today announced that it has completed enrollment in the ...
In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”), the event-driven ...
Preliminary insights from the Phase III trial are anticipated to be available in 2027.
Study to evaluate ficerafusp alfa in combination with pembrolizumab as a loading and every-three-week maintenance regimen in 1L R/M HPV-negative HNSCC expected to initiate in Q3 2026 Long-term follow- ...
Clinical trial recruitment is currently ongoing for lung, breast, pancreatic, colorectal, and uterine cancers, the deadliest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results